123 related articles for article (PubMed ID: 8195835)
1. In vitro brodimoprim activity on bacterial strains.
Benoit-Lemercier C; Bergogne-Bérézin E; Joly-Guillou ML
J Chemother; 1993 Dec; 5(6):435-43. PubMed ID: 8195835
[TBL] [Abstract][Full Text] [Related]
2. In vitro brodimoprim activity on nosocomial bacterial strains.
Nicoletti P; Novelli A; Periti P
J Chemother; 1993 Dec; 5(6):430-4. PubMed ID: 8195834
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
6. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents.
Focht J; Klietmann W; Nösner K
Arzneimittelforschung; 1988 Aug; 38(8):1085-8. PubMed ID: 3264166
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
9. [In vitro antibacterial activity of rokitamycin, a new macrolide antibiotic. Results of a multicenter study].
Soussy CJ; Le Van Thoi J; Meyran M; Joly B; Derlot E; Morel C
Pathol Biol (Paris); 1990 May; 38(5):407-12. PubMed ID: 2195450
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
11. [Comparative in vitro bacteriostatic and bactericidal effect of 5 macrolides: roxithromycin, erythromycin, oleandomycin, josamycin and spiramycin against 284 hospital bacterial strains].
Le Noc P; Croize J; Bryskier A; Le Noc D; Robert J
Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):553-9. PubMed ID: 2797879
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
13. [In vitro antibacterial activity of clarithromycin, a new macrolide antibiotic, and regression curve].
Soussy CJ; Le Van Thoi J; Cluzel M; Derlot E; Kitzis MD
Pathol Biol (Paris); 1990 May; 38(5):401-6. PubMed ID: 2142274
[TBL] [Abstract][Full Text] [Related]
14. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial activity of Achillea clavennae essential oil against respiratory tract pathogens.
Skocibusić M; Bezić N; Dunkić V; Radonić A
Fitoterapia; 2004 Dec; 75(7-8):733-6. PubMed ID: 15567252
[TBL] [Abstract][Full Text] [Related]
16. Minimum inhibitory concentration determinations for various antimicrobial agents against 1570 bacterial isolates from turkey poults.
Salmon SA; Watts JL
Avian Dis; 2000; 44(1):85-98. PubMed ID: 10737648
[TBL] [Abstract][Full Text] [Related]
17. Bacterial pathogens (non-Mycobacterium) from sputum culture and antimicrobial susceptibility.
Srifuengfung S; Sangsawang M; Komolpis P; Dhiraputra C; Chompanee B
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):96-9. PubMed ID: 9740278
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro activity of roxithromycin, a new macrolide antibiotic, in comparison with that of erythromycin.
King A; Phillips I
Drugs Exp Clin Res; 1987; 13(9):563-6. PubMed ID: 3428135
[TBL] [Abstract][Full Text] [Related]
20. Patterns of isolation of common gram positive bacterial pathogens and their susceptibilities to antimicrobial agents in Jimma Hospital.
Gebreselassie S
Ethiop Med J; 2002 Apr; 40(2):115-27. PubMed ID: 12240573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
